Presentations and publications

March 12, 2020 | JCI Insight
Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity
November 12, 2019 | SITC 2019
CTX-8371, a Novel Bispecific Targeting both PD-1 and PD-L1, is more Potent than Combination anti-PD-1 and PD-L1 Therapy and Provides Enhanced Protection from Tumors in vivo
November 12, 2019 | SITC 2019
A novel class of Innate Cell Engagers targeting NKp30
April 10, 2019 | Keystone Symposia Conference: “D2: Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies”
Novel class of NK engagers targeting NKp30 selected from unbiased screen of common light chain based bispecific antibodies
April 9, 2019 | Keystone Symposia Conference: “D2: Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies”
A versatile platform for efficient affinity optimization of common light chain multi-specific antibodies
March 25, 2019 | AACR Annual Meeting 2019
Preclinical characterization of NKp30xBCMA, a novel class of NK‐Cell Engagers
March 25, 2019 | Keystone Cancer Immunology Symposium
A Novel Class of NK-Cell Engagers Targeting NKp30
November 10, 2018 | SITC 2018
CTX-471, a novel agonistic antibody targeting CD137, eradicates very large tumors by selectively reprogramming the tumor microenvironment without causing hepatic toxicity
November 10, 2018 | SITC 2018
CTX-471, a novel agonistic antibody targeting CD137, enhances the anti-tumor activity of tumor antigen-targeted antibodies and immune checkpoint inhibitors when used in combination
November 10, 2018 | SITC 2018
A novel class of NK cell engagers overcomes CD16A deficiency